Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?

CONMED Corporation CNMD presents investors with a clear trade-off. The stock’s valuation is inexpensive relative to key benchmarks, while operating trends and the 2026 earnings outlook have improved.

The offset is execution risk. Cash flow, supply-chain work and higher financing costs still leave limited room for missteps, making the buy-versus-wait decision less straightforward.

CNMD Trades Below Key Valuation Benchmarks

CNMD trades at 10.82X forward 12-month earnings, below 17.71X for its Zacks sub-industry and 21.07X for the broader Zacks Medical sector. The current multiple is also well below the stock’s five-year median of 18.49X, underscoring the valuation discount.

Image Source: Zacks Investment Research

Stryker Corporation SYK is a useful medtech reference because its portfolio spans MedSurg and Orthopaedics. Medtronic plc MDT also provides relevant context through its surgical robotics and other surgical technology offerings. CNMD’s discount may attract value-oriented investors, but valuation alone does not resolve its company-specific execution risks.

CONMED’s Earnings Outlook Has Improved

Management raised 2026 adjusted earnings guidance to $4.48-$4.60 per share from $4.30-$4.45 after better-than-expected second-quarter results. The higher range reflects a lower expected earnings headwind from the gastroenterology exit and a larger contribution from share repurchases.

Those benefits are partly offset by higher interest expense and a higher tax-rate assumption. The revised outlook still marks a better earnings setup than management projected earlier in the year.

CNMD’s Portfolio Focus Supports Cleaner Growth

CONMED completed its gastroenterology exit in the second quarter, sharpening its focus on minimally invasive surgery, smoke evacuation and orthopedic soft-tissue repair. That leaves AirSeal, Buffalo Filter and BioBrace at the center of the company’s growth strategy.

Second-quarter organic constant-currency revenues excluding gastroenterology increased 6%, even though total constant-currency revenues declined 0.5%. The gap shows how the divestiture is still distorting reported growth while the remaining portfolio is expanding at a healthier pace.

CONMED Still Has Little Room for Execution Errors

Supply-chain conditions have improved, with service levels strengthening and backorders at multi-year lows, but the transformation is not finished. Inventories rose to $360.2 million at June 30 from $355.5 million at year-end as CONMED built supply to reduce stock-out risk.

Financing and cash-flow pressure add another constraint. Expected 2026 adjusted interest expense increased to about $33 million from $25-$27 million, while free cash flow guidance fell to about $115 million from roughly $125 million. Original equipment manufacturer smoke demand can also create quarterly volatility.

CONMED Corporation PEG Ratio (TTM)

CONMED Corporation peg-ratio-ttm | CONMED Corporation Quote

CNMD’s Value Signal Outweighs Its Growth Scores

The valuation case is stronger than the near-term growth signal, but that does not make CNMD an automatic buy. Improving earnings, cleaner portfolio exposure and organic growth support the case for holding or selective accumulation, while execution and cash conversion argue for patience.

CNMD currently carries a Zacks Rank #3 (Hold). It also has a Value Score of A, Growth Score of C, Momentum Score of C and VGM Score of B. The Value Score highlights relative valuation appeal, while the Growth and Momentum scores are more neutral. Likewise, Stryker and Medtronic also carry a Zacks Rank of 3. With a Zacks Rank #3, the combined signals favor a balanced stance rather than a decisive buy call. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research